ArticleScientific reports2026
Cholangiocarcinoma derived exosomes attenuate the anti-tumor functions of NK cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Natural killer (NK) cells play critical roles in anti-tumor immunity however are always frustrated in some solid tumors. Tumor derived exosomes usually facilitate tumor progression via regulating immune cells functions. The effects of CCA (cholangiocarcinoma)-derived exosomes (CCA-Exos) on NK cells functions remain unclear. The objective of this study was to investigate whether and how the CCA-Exos affect the NK cells anti-tumor activity. Immunohistochemical staining displayed that the infiltration of NK cells decreased obviously in tumor lesions compared with the paracancerous tissues. Exosomes were isolated from human primary cholangiocarcinoma cell lines (RBE cells), patients and healthy people serum. Flow cytometry assay revealed that both exosomes from patient serum and RBE cells induced apoptosis of NK-92 cells. BCL-2 and BCL-XL were downregulated by RBE cells exosomes in both of transcriptional and protein levels. Besides, exosomes-treated NK-92 cells lost the normal clustered growing as well as the lower expression of adhesion molecules of CD11a, CD18 and CD54 and decreased production of IFN-γ and granzyme B. The killing activity of NK-92 cells against target cells was also attenuated by exosomes. NK cells in the peripheral blood of CCA patients also showed significantly lower cytotoxicity and expression of adhesion molecules compared to NK cells in the peripheral blood of healthy people. However, the proliferation of NK-92 cells was not affected by exosomes. This study suggests that cholangiocarcinoma may escape the immune surveillance by suppressing the NK cell functions from multiple aspects through exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.